Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
3011 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Breast Cancer - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Breast Cancer - Pipeline Review, H1 2016', provides an overview of the Breast Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Breast Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Breast Cancer - The report reviews pipeline therapeutics for Breast Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Breast Cancer therapeutics and enlists all their major and minor projects - The report assesses Breast Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Breast Cancer Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Breast Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 15 Breast Cancer Overview 16 Therapeutics Development 17 Breast Cancer - Therapeutics under Development by Companies 19 Breast Cancer - Therapeutics under Investigation by Universities/Institutes 59 Breast Cancer - Pipeline Products Glance 68 Breast Cancer - Products under Development by Companies 72 Breast Cancer - Products under Investigation by Universities/Institutes 134 Breast Cancer - Companies Involved in Therapeutics Development 148 Breast Cancer - Therapeutics Assessment 582 Drug Profiles 693 Breast Cancer - Dormant Projects 2810 Breast Cancer - Discontinued Products 2869 Breast Cancer - Product Development Milestones 2881 Appendix 2893
List of Tables
Number of Products under Development for Breast Cancer, H1 2016 134 Number of Products under Development for Breast Cancer - Comparative Analysis, H1 2016 135 Number of Products under Development by Companies, H1 2016 137 Number of Products under Development by Companies, H1 2016 (Contd..1) 138 Number of Products under Development by Companies, H1 2016 (Contd..2) 139 Number of Products under Development by Companies, H1 2016 (Contd..3) 140 Number of Products under Development by Companies, H1 2016 (Contd..4) 141 Number of Products under Development by Companies, H1 2016 (Contd..5) 142 Number of Products under Development by Companies, H1 2016 (Contd..6) 143 Number of Products under Development by Companies, H1 2016 (Contd..7) 144 Number of Products under Development by Companies, H1 2016 (Contd..8) 145 Number of Products under Development by Companies, H1 2016 (Contd..9) 146 Number of Products under Development by Companies, H1 2016 (Contd..10) 147 Number of Products under Development by Companies, H1 2016 (Contd..11) 148 Number of Products under Development by Companies, H1 2016 (Contd..12) 149 Number of Products under Development by Companies, H1 2016 (Contd..13) 150 Number of Products under Development by Companies, H1 2016 (Contd..14) 151 Number of Products under Development by Companies, H1 2016 (Contd..15) 152 Number of Products under Development by Companies, H1 2016 (Contd..16) 153 Number of Products under Development by Companies, H1 2016 (Contd..17) 154 Number of Products under Development by Companies, H1 2016 (Contd..18) 155 Number of Products under Development by Companies, H1 2016 (Contd..19) 156 Number of Products under Development by Companies, H1 2016 (Contd..20) 157 Number of Products under Development by Companies, H1 2016 (Contd..21) 158 Number of Products under Development by Companies, H1 2016 (Contd..22) 159 Number of Products under Development by Companies, H1 2016 (Contd..23) 160 Number of Products under Development by Companies, H1 2016 (Contd..24) 161 Number of Products under Development by Companies, H1 2016 (Contd..25) 162 Number of Products under Development by Companies, H1 2016 (Contd..26) 163 Number of Products under Development by Companies, H1 2016 (Contd..27) 164 Number of Products under Development by Companies, H1 2016 (Contd..28) 165 Number of Products under Development by Companies, H1 2016 (Contd..29) 166 Number of Products under Development by Companies, H1 2016 (Contd..30) 167 Number of Products under Development by Companies, H1 2016 (Contd..31) 168 Number of Products under Development by Companies, H1 2016 (Contd..32) 169 Number of Products under Development by Companies, H1 2016 (Contd..33) 170 Number of Products under Development by Companies, H1 2016 (Contd..34) 171 Number of Products under Development by Companies, H1 2016 (Contd..35) 172 Number of Products under Development by Companies, H1 2016 (Contd..36) 173 Number of Products under Development by Companies, H1 2016 (Contd..37) 174 Number of Products under Development by Companies, H1 2016 (Contd..38) 175 Number of Products under Investigation by Universities/Institutes, H1 2016 176 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 177 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 178 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 179 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 180 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..5) 181 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..6) 182 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..7) 183 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..8) 184 Comparative Analysis by Late Stage Development, H1 2016 185 Comparative Analysis by Clinical Stage Development, H1 2016 186 Comparative Analysis by Early Stage Development, H1 2016 187 Comparative Analysis by Unknown Stage Development, H1 2016 188 Products under Development by Companies, H1 2016 189 Products under Development by Companies, H1 2016 (Contd..1) 190 Products under Development by Companies, H1 2016 (Contd..2) 191 Products under Development by Companies, H1 2016 (Contd..3) 192 Products under Development by Companies, H1 2016 (Contd..4) 193 Products under Development by Companies, H1 2016 (Contd..5) 194 Products under Development by Companies, H1 2016 (Contd..6) 195 Products under Development by Companies, H1 2016 (Contd..7) 196 Products under Development by Companies, H1 2016 (Contd..8) 197 Products under Development by Companies, H1 2016 (Contd..9) 198 Products under Development by Companies, H1 2016 (Contd..10) 199 Products under Development by Companies, H1 2016 (Contd..11) 200 Products under Development by Companies, H1 2016 (Contd..12) 201 Products under Development by Companies, H1 2016 (Contd..13) 202 Products under Development by Companies, H1 2016 (Contd..14) 203 Products under Development by Companies, H1 2016 (Contd..15) 204 Products under Development by Companies, H1 2016 (Contd..16) 205 Products under Development by Companies, H1 2016 (Contd..17) 206 Products under Development by Companies, H1 2016 (Contd..18) 207 Products under Development by Companies, H1 2016 (Contd..19) 208 Products under Development by Companies, H1 2016 (Contd..20) 209 Products under Development by Companies, H1 2016 (Contd..21) 210 Products under Development by Companies, H1 2016 (Contd..22) 211 Products under Development by Companies, H1 2016 (Contd..23) 212 Products under Development by Companies, H1 2016 (Contd..24) 213 Products under Development by Companies, H1 2016 (Contd..25) 214 Products under Development by Companies, H1 2016 (Contd..26) 215 Products under Development by Companies, H1 2016 (Contd..27) 216 Products under Development by Companies, H1 2016 (Contd..28) 217 Products under Development by Companies, H1 2016 (Contd..29) 218 Products under Development by Companies, H1 2016 (Contd..30) 219 Products under Development by Companies, H1 2016 (Contd..31) 220 Products under Development by Companies, H1 2016 (Contd..32) 221 Products under Development by Companies, H1 2016 (Contd..33) 222 Products under Development by Companies, H1 2016 (Contd..34) 223 Products under Development by Companies, H1 2016 (Contd..35) 224 Products under Development by Companies, H1 2016 (Contd..36) 225 Products under Development by Companies, H1 2016 (Contd..37) 226 Products under Development by Companies, H1 2016 (Contd..38) 227 Products under Development by Companies, H1 2016 (Contd..39) 228 Products under Development by Companies, H1 2016 (Contd..40) 229 Products under Development by Companies, H1 2016 (Contd..41) 230 Products under Development by Companies, H1 2016 (Contd..42) 231 Products under Development by Companies, H1 2016 (Contd..43) 232 Products under Development by Companies, H1 2016 (Contd..44) 233 Products under Development by Companies, H1 2016 (Contd..45) 234 Products under Development by Companies, H1 2016 (Contd..46) 235 Products under Development by Companies, H1 2016 (Contd..47) 236 Products under Development by Companies, H1 2016 (Contd..48) 237 Products under Development by Companies, H1 2016 (Contd..49) 238 Products under Development by Companies, H1 2016 (Contd..50) 239 Products under Development by Companies, H1 2016 (Contd..51) 240 Products under Development by Companies, H1 2016 (Contd..52) 241 Products under Development by Companies, H1 2016 (Contd..53) 242 Products under Development by Companies, H1 2016 (Contd..54) 243 Products under Development by Companies, H1 2016 (Contd..55) 244 Products under Development by Companies, H1 2016 (Contd..56) 245 Products under Development by Companies, H1 2016 (Contd..57) 246 Products under Development by Companies, H1 2016 (Contd..58) 247 Products under Development by Companies, H1 2016 (Contd..59) 248 Products under Development by Companies, H1 2016 (Contd..60) 249 Products under Development by Companies, H1 2016 (Contd..61) 250 Products under Investigation by Universities/Institutes, H1 2016 251 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 252 Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 253 Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 254 Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 255 Products under Investigation by Universities/Institutes, H1 2016 (Contd..5) 256 Products under Investigation by Universities/Institutes, H1 2016 (Contd..6) 257 Products under Investigation by Universities/Institutes, H1 2016 (Contd..7) 258 Products under Investigation by Universities/Institutes, H1 2016 (Contd..8) 259 Products under Investigation by Universities/Institutes, H1 2016 (Contd..9) 260 Products under Investigation by Universities/Institutes, H1 2016 (Contd..10) 261 Products under Investigation by Universities/Institutes, H1 2016 (Contd..11) 262 Products under Investigation by Universities/Institutes, H1 2016 (Contd..12) 263 Products under Investigation by Universities/Institutes, H1 2016 (Contd..13) 264 Breast Cancer - Pipeline by 3-V Biosciences, Inc., H1 2016 265 Breast Cancer - Pipeline by 4SC AG, H1 2016 266 Breast Cancer - Pipeline by A&G Pharmaceutical, Inc., H1 2016 267 Breast Cancer - Pipeline by AB Science SA, H1 2016 268 Breast Cancer - Pipeline by AbbVie Inc., H1 2016 269 Breast Cancer - Pipeline by AbGenomics International, Inc., H1 2016 270 Breast Cancer - Pipeline by Ability Pharmaceuticals, S.L., H1 2016 271 Breast Cancer - Pipeline by Acceleron Pharma, Inc., H1 2016 272 Breast Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 273 Breast Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 274 Breast Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016 275 Breast Cancer - Pipeline by ADC Therapeutics Sarl, H1 2016 276 Breast Cancer - Pipeline by Adgero Biopharmaceuticals, Inc., H1 2016 277 Breast Cancer - Pipeline by Aduro BioTech, Inc., H1 2016 278 Breast Cancer - Pipeline by Advanced Accelerator Applications S.A., H1 2016 279 Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2016 280 Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corporation, H1 2016 281 Breast Cancer - Pipeline by Advaxis, Inc., H1 2016 282 Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 283 Breast Cancer - Pipeline by Aegis Therapeutics, LLC, H1 2016 284 Breast Cancer - Pipeline by Aeglea BioTherapeutics, Inc., H1 2016 285 Breast Cancer - Pipeline by Aerpio Therapeutics, Inc., H1 2016 286 Breast Cancer - Pipeline by Aeterna Zentaris Inc., H1 2016 287 Breast Cancer - Pipeline by Affichem SA, H1 2016 288 Breast Cancer - Pipeline by Agenus, Inc., H1 2016 289 Breast Cancer - Pipeline by Agilvax, Inc., H1 2016 290 Breast Cancer - Pipeline by Aileron Therapeutics, Inc., H1 2016 291 Breast Cancer - Pipeline by Alchemia Limited, H1 2016 292 Breast Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2016 293 Breast Cancer - Pipeline by Almac Discovery Limited, H1 2016 294 Breast Cancer - Pipeline by Alteogen Inc., H1 2016 295 Breast Cancer - Pipeline by Amarna Therapeutics B.V., H1 2016 296 Breast Cancer - Pipeline by Ambrx, Inc., H1 2016 297 Breast Cancer - Pipeline by American Gene Technologies International Inc., H1 2016 298 Breast Cancer - Pipeline by Amgen Inc., H1 2016 299 Breast Cancer - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016 300 Breast Cancer - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2016 301 Breast Cancer - Pipeline by Angion Biomedica Corp., H1 2016 302 Breast Cancer - Pipeline by ANP Technologies, Inc., H1 2016 303 Breast Cancer - Pipeline by AntiCancer, Inc., H1 2016 304 Breast Cancer - Pipeline by Antigen Express, Inc., H1 2016 305 Breast Cancer - Pipeline by Antoxis Limited, H1 2016 306 Breast Cancer - Pipeline by Aphios Corporation, H1 2016 307 Breast Cancer - Pipeline by APIM Therapeutics AS, H1 2016 308
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
